2017.11.3 NanoCarrier and VBL Therapeutics Conclude License Agreement for Gene-Therapy Agent in Japan
- Non-replicating Adeno 5 vectors
- Systemically administered via intravenous injection
- Selectively induce cell death in angiogenic endothelial cells
- Triggers a local anti-tumor immune response
- POC verified for other solid cancers
（Please note that sound will flow）
Development by VBL is progressing mainly in the United States.